Table 2.
Clinical details and follow-up for patients with persistent HIV-1 RNA ≥ 50 copies/mL (N = 7)
| Regimen prior to DCR switch | Baseline DCR | Baseline RAMs | Active ARVs in DCR | HIV-1 RNA (cps/mL) | Suspected reason for non-response | Treatment-emergent RAMs | Date of DCR DC and new ARV regimen | HIV-1 RNA following DCR DC (cps/mL) | |
|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | TDF/FTC/DRV/r/RAL | DTG + TDF/FTC | M184V/I | DTG + TDF |
BL: < 50 W24: 50, 51 W48: 2598 |
Unclear, 100% compliance reported | No post-treatment GT | DC at W48, changed to ETR/DRV/r/DTG | W52: < 50 on new regimen |
| Patient 2 | TDF/FTC/DRV/r/ETR | DTG + ABC/3TC | M184V/I | DTG + ABC |
BL: < 50 W12: 250 W52:1023 |
Non-compliance | None, GT performed 9 months after W52 | DC at W52, changed to ABC/3TC/DTG/DRV/r | W55: < 50 on new regimen |
| Patient 3 | TDF/FTC/DRV/r | DTG/ABC/3TC | M184V/I | DTG + ABC |
BL: < 50 W8: < 50 W28: < 50 W48: 80, 90 |
Unclear, 100% compliance reported | No post-treatment GT | DC at W48, switched to DTG/DRV/c | W56: < 50 on new regimen |
| Patient 4 | TDF/FTC/DRV/r | DTG + TDF/FTC | M41L, M184V/I, T215Y | DTG + TDF |
BL: 70 W8: 30 W16: 130 W32: 570 W48: 120 |
Non-compliance | None, GT performed 2 weeks after W48 | DC at W48, switch to ETR/TDF/FTC/DRV/r | W53: < 50 on new regimen |
| Patient 5 | ABC/3TC/DRV/r | DTG + RPV | M184V/I, E138E/K | DTG |
BL: 170 W20: 320 W28: 130 W40: 150 W56: 600 W80: 90 W92: 120 W104: 210 |
Non-compliance | None, GT performed 16 months after W104 | DC at W104, changed to DTG/DRV/c | W108: < 50 on new regimen |
| Patient 6 | TDF/FTC/EVG/c | DTG + ABC/3TC | M184V/I, M41L, T215Y, L74L/I | DTG |
BL: 280 W4: 90 W12: 90 W24: 110 |
Non-compliance | None, GT performed 4 weeks after W24 | DC at W24, changed to DTG/DRV/r |
W48: 60 W52: < 50 on new regimen |
| Patient 7 | ABC/3TC/FPV/r | DTG + ABC/3TC | M184V/I | DTG + ABC |
BL: 1400 W4: < 50 W36: 724, 801 |
Non-compliance | None, GT performed 2 weeks after W36 | Regimen continued, LTFU after W36 | LTFU after W36 |
DCR dolutegravir containing regimen, RAM resistance associated mutation, ARV antiretroviral, DC discontinuation, DTG dolutegravir, TDF tenofovir, FTC emtricitabine, DRV darunavir, r ritonavir, RAL raltegravir, ABC abacavir, 3TC lamivudine, EVG elvitegravir, c cobicistat, FPV fosamprenavir, RPV rilpivirine, BL baseline, W week, GT genotype, ETR etravirine, LTFU lost to follow up